Saxagliptin hydrate
- Saxagliptin hydrate
- 945667-22-1
- saxagliptin monohydrate
- Onglyza
- Saxagliptin (hydrate)
- Create:2011-08-02
- Modify:2024-12-07
- 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate
- BMS 477118
- BMS-477118
- BMS477118
- Onglyza
- saxagliptin
- Saxagliptin hydrate
- 945667-22-1
- saxagliptin monohydrate
- Onglyza
- Saxagliptin (hydrate)
- 9GB927LAJW
- BMS-477118-11
- (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile;hydrate
- CHEBI:71271
- NSC-760407
- (1S,3S,5S)-2-[(2S)-2-Amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate(1:1)
- Onglyza (TN)
- Saxagliptin hydrate (JAN)
- SAXAGLIPTIN HYDRATE [JAN]
- Onglyza hydrate
- (1S,3S,5S)-2-((2S)-2-Amino-2-(3-hydroxyadamantan-1-yl)acetyl)-2-azabicyclo[3.1.0]hexane-3-carbonitrile monohydrate
- Saxagliptin [USAN]
- BMS-477118
- BMS477118 hydrate
- BMS 477118 hydrate
- UNII-9GB927LAJW
- Saxagliptin [USAN:INN:BAN]
- Saxagliptin Monohydrate; (1S,?3S,?5S)?-2-?[(2S)?-?2-?Amino-?2-?(3-?hydroxytricyclo[3.3.?1.13,?7]?dec-?1-?yl)?acetyl]?-?2-?azabicyclo[3.1.0]?hexane-?3-?carbonitrile Hydrate
- SAXAGLIPTIN [VANDF]
- SAXAGLIPTIN [MART.]
- CHEMBL2103745
- AFNTWHMDBNQQPX-NHKADLRUSA-N
- SAXAGLIPTIN MONOHYDRATE [MI]
- BMS477118
- HY-10285A
- QTERNMET COMPONENT SAXAGLIPTIN
- s4697
- AKOS024462870
- CCG-267844
- CS-3250
- NSC 760407
- SAXAGLIPTIN MONOHYDRATE [WHO-DD]
- AS-75156
- DA-57687
- D09753
- Q27139483
- 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate
- (1S,3S,5S)-2-((2S)-AMINO(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE MONOHYDRATE
- (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)2- azabicyclo(3.1.0)hexane-3-carbonitrile monohydrate
- (1S,3S,5S)-2-((2S)-Amino(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)2-azabicyclo(3.1.0)hexane-3-carbonitrile monohydrate
- (1s,3s,5s)-2-[(2s)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate
- (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile--water (1/1)
- (1S,3S,5S)-2-[(2S)-2-amino-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile hydrate
- 2-AZABICYCLO(3.1.0)HEXANE-3-CARBONITRILE, 2-((2S)-2-AMINO-2-(3-HYDROXYTRICYCLO(3.3.1.1(SUP 3,7))DEC-1-YL)ACETYL)-, HYDRATE (1:1), (1S,3S,5S)-
- 2-Azabicyclo(3.1.0)hexane-3-carbonitrile, 2-((2S)-2-amino-2-(3-hydroxytricyclo(3.3.1.13,7)dec-1-yl)acetyl)-, hydrate (1:1), (1S,3S,5S)-
H317 (90.9%): May cause an allergic skin reaction [Warning Sensitization, Skin]
H334 (81.8%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]
H361 (90.9%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
H372 (81.8%): Causes damage to organs through prolonged or repeated exposure [Danger Specific target organ toxicity, repeated exposure]
P203, P233, P260, P261, P264, P270, P271, P272, P280, P284, P302+P352, P304+P340, P318, P319, P321, P333+P317, P342+P316, P362+P364, P403, P405, and P501
(The corresponding statement to each P-code can be found at the GHS Classification page.)
Aggregated GHS information provided per 11 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.
Skin Sens. 1A (90.9%)
Resp. Sens. 1A (81.8%)
Repr. 2 (90.9%)
STOT RE 1 (81.8%)
◉ Summary of Use during Lactation
No information is available on the clinical use of saxagliptin during breastfeeding. Saxagliptin has a shorter half-life than the other dipeptidyl-peptidase IV inhibitors, so it might be a better choice among drugs in this class for nursing mothers. Monitoring of the breastfed infant's blood glucose is advisable during maternal therapy with saxagliptin.[1] However, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
◉ Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
◉ Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Patents are available for this chemical structure:
https://patentscope.wipo.int/search/en/result.jsf?inchikey=AFNTWHMDBNQQPX-NHKADLRUSA-N
- CAS Common ChemistryLICENSEThe data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated.https://creativecommons.org/licenses/by-nc/4.0/Saxagliptin hydratehttps://commonchemistry.cas.org/detail?cas_rn=945667-22-1
- ChemIDplusSaxagliptin [USAN:INN:BAN]https://pubchem.ncbi.nlm.nih.gov/substance/?source=chemidplus&sourceid=0945667221ChemIDplus Chemical Information Classificationhttps://pubchem.ncbi.nlm.nih.gov/source/ChemIDplus
- European Chemicals Agency (ECHA)LICENSEUse of the information, documents and data from the ECHA website is subject to the terms and conditions of this Legal Notice, and subject to other binding limitations provided for under applicable law, the information, documents and data made available on the ECHA website may be reproduced, distributed and/or used, totally or in part, for non-commercial purposes provided that ECHA is acknowledged as the source: "Source: European Chemicals Agency, http://echa.europa.eu/". Such acknowledgement must be included in each copy of the material. ECHA permits and encourages organisations and individuals to create links to the ECHA website under the following cumulative conditions: Links can only be made to webpages that provide a link to the Legal Notice page.https://echa.europa.eu/web/guest/legal-notice(1S, 3S, 5S)-2-((2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyle)-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydratehttps://echa.europa.eu/substance-information/-/substanceinfo/100.168.859(1S, 3S, 5S)-2-((2S)-2-amino-2-(3-hydroxyadamantan-1-yl)acetyle)-2-azabicyclo[3.1.0]hexane-3-carbonitrile, monohydrate (EC: 641-082-3)https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/173742
- FDA Global Substance Registration System (GSRS)LICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- ChEBISaxagliptin hydratehttps://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:71271
- NCI Thesaurus (NCIt)LICENSEUnless otherwise indicated, all text within NCI products is free of copyright and may be reused without our permission. Credit the National Cancer Institute as the source.https://www.cancer.gov/policies/copyright-reuseNCI Thesaurushttps://ncit.nci.nih.gov
- Open TargetsLICENSEDatasets generated by the Open Targets Platform are freely available for download.https://platform-docs.opentargets.org/licence
- ChEMBLLICENSEAccess to the web interface of ChEMBL is made under the EBI's Terms of Use (http://www.ebi.ac.uk/Information/termsofuse.html). The ChEMBL data is made available on a Creative Commons Attribution-Share Alike 3.0 Unported License (http://creativecommons.org/licenses/by-sa/3.0/).http://www.ebi.ac.uk/Information/termsofuse.html
- ClinicalTrials.govLICENSEThe ClinicalTrials.gov data carry an international copyright outside the United States and its Territories or Possessions. Some ClinicalTrials.gov data may be subject to the copyright of third parties; you should consult these entities for any additional terms of use.https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use
- Drugs and Lactation Database (LactMed)
- Drugs@FDALICENSEUnless otherwise noted, the contents of the FDA website (www.fda.gov), both text and graphics, are not copyrighted. They are in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from FDA. Credit to the U.S. Food and Drug Administration as the source is appreciated but not required.https://www.fda.gov/about-fda/about-website/website-policies#linking
- European Medicines Agency (EMA)LICENSEInformation on the European Medicines Agency's (EMA) website is subject to a disclaimer and copyright and limited reproduction notices.https://www.ema.europa.eu/en/about-us/legal-noticeOnglyza (EMEA/H/C/001039)https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza
- EU Clinical Trials Register
- KEGGLICENSEAcademic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial licensehttps://www.kegg.jp/kegg/legal.htmlTherapeutic category of drugs in Japanhttp://www.genome.jp/kegg-bin/get_htext?br08301.kegUSP drug classificationhttp://www.genome.jp/kegg-bin/get_htext?br08302.kegAnatomical Therapeutic Chemical (ATC) classificationhttp://www.genome.jp/kegg-bin/get_htext?br08303.kegTarget-based classification of drugshttp://www.genome.jp/kegg-bin/get_htext?br08310.keg
- NLM RxNorm TerminologyLICENSEThe RxNorm Terminology is created by the National Library of Medicine (NLM) and is in the public domain and may be republished, reprinted and otherwise used freely by anyone without the need to obtain permission from NLM. Credit to the U.S. National Library of Medicine as the source is appreciated but not required. The full RxNorm dataset requires a free license.https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.htmlsaxagliptinhttps://rxnav.nlm.nih.gov/id/rxnorm/857974
- Springer Nature
- Wikidatasaxagliptin hydratehttps://www.wikidata.org/wiki/Q27139483
- PubChem
- Medical Subject Headings (MeSH)LICENSEWorks produced by the U.S. government are not subject to copyright protection in the United States. Any such works found on National Library of Medicine (NLM) Web sites may be freely used or reproduced without permission in the U.S.https://www.nlm.nih.gov/copyright.htmlsaxagliptinhttps://www.ncbi.nlm.nih.gov/mesh/67502994Dipeptidyl-Peptidase IV Inhibitorshttps://www.ncbi.nlm.nih.gov/mesh/68054873
- GHS Classification (UNECE)GHS Classification Treehttp://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html
- MolGenieMolGenie Organic Chemistry Ontologyhttps://github.com/MolGenie/ontology/
- PATENTSCOPE (WIPO)SID 392142151https://pubchem.ncbi.nlm.nih.gov/substance/392142151